Online nicotine retailer Haypp has voluntarily adopted a 20 mg per pouch cap across its e-commerce platforms and is urging the UK government to formalize that as the limit as it develops a regulatory framework under its Tobacco and Vapes Bill. The company, which serves more than 1.1 million customers globally, says proportionate limits would protect consumers while preserving nicotine pouches as a viable reduced-risk alternative to cigarettes. Dr. Marina Murphy, Haypp’s senior director of scientific affairs, said a 20 mg maximum provides a nicotine experience comparable to smoking without enabling “ultra-strength” products to proliferate, with some reportedly containing up to 150 mg per pouch.
Tag: Haypp
-
Study Warns Gen Z Getting Misinformation on Smoking, Vaping
Declining smoking rates in the UK have been partly attributed to smokers switching to vaping, with daily smoking falling from 20.2% in 2011 to 9.1% in 2024, according to NHS data. However, growing misperceptions about the relative risks of vaping may be undermining that progress, particularly among younger adults. A long-term study by University College London found that the proportion of smokers who believed e-cigarettes were less harmful than cigarettes dropped from 44% in 2014 to 27% in 2023, while a majority came to believe vaping is as harmful or more harmful than smoking. Separate research from Action on Smoking and Health (ASH) reported that 56% of adults and 63% of young people now hold that view.
Markus Lindblad, head of external affairs at Haypp, argues that sustained negative media coverage and online misinformation are contributing to confusion about relative risk, potentially discouraging smokers from switching to alternatives. He contends that for Gen Z—who may have had less exposure to traditional anti-smoking campaigns—frequent warnings about vaping, combined with less visible messaging about the harms of combustible tobacco, may distort perceptions. Public health bodies including the Royal College of Physicians have previously called for clearer communication to address false beliefs about nicotine alternatives, while continuing to support enforcement measures to curb youth uptake.
“For Gen Z, who may not have had the same exposure to anti-smoking information as previous generations, they are encountering negative information about vapes far more frequently than negative information about cigarettes,” Lindblad said. “It is unsurprising, then, that their understanding of the relative risk between vapes and cigarettes is inaccurate.”
-
Pouch Boom Disrupting Scandinavian Tradition: Report
A report tracking more than 19 million online purchases between 2018 and 2025 suggests nicotine pouches are rapidly overtaking traditional snus in Sweden and Norway, signaling a cultural shift in Scandinavia’s long-standing oral nicotine market. The research found that tobacco-free nicotine pouches now account for the largest share of oral nicotine sales on leading regional e-commerce platforms, as consumers move away from tobacco-based snus. Globally, nicotine pouch sales have surged from roughly 292 million units in 2018 to more than 20 billion in 2023, with strong growth also reported in the UK and U.S. Study co-author Dr. Marina Murphy of Haypp Group said many users perceive pouches as a lower-risk alternative, underscoring the need for public health authorities to closely monitor the fast-evolving category and its broader implications.
-
Nicotine Pouch Growth Drives Haypp’s 5% Sales Increase
Haypp Group reported strong global growth in nicotine pouches (NPs), with Q4 2025 volume up 28%, driven by the U.S. reintroduction of Zyn in September 2025 and accelerating growth in the UK. NPs now account for 67% of total volume, with FY25 volume up 13% year-over-year. U.S. consumer offtake rose approximately 35% in Q4 2025 and January 2026 volumes jumped 120% year-over-year, with new customer acquisition up over 250%. The company cited improved retention through localized teams, research, and consumer-focused initiatives, achieving an all-time high Net Promoter Score of 82. In the UK, Q4 2025 volume rose 73% and new customer growth reached 112%, accelerating to ~200% and ~125%, respectively, in January.
Looking ahead, Haypp anticipates regulatory changes in Austria will force an exit by mid-2026, though this market represents less than 1% of total sales. The company strengthened its U.S. infrastructure, increasing overhead by 29% to support Media and Insights and online growth initiatives. Leverage stood at 0.6x net debt/adjusted EBITDA at year-end, with inventory tactically increased ahead of January 2026 price hikes. Haypp’s Board reaffirmed 2028 targets: 18–25% annual revenue growth, an adjusted EBIT margin of 5.5% ±150 bps, and reinvestment of cash flows to support ongoing expansion in its core U.S. and UK markets while maintaining compliance as a competitive advantage.
-
PMI Positive After FDA’s Zyn Hearing
Philip Morris International (PMI) believes it moved a step closer to securing permission to market its Zyn nicotine pouches as a reduced-risk alternative to cigarettes in the United States, following a full-day public hearing convened by the U.S. Food and Drug Administration (FDA) yesterday (January 22). At the meeting, PMI scientists presented evidence to the FDA’s Tobacco Products Scientific Advisory Committee (TPSAC) in support of a Modified Risk Tobacco Product (MRTP) application that would allow the company to tell adult smokers that switching completely to Zyn lowers the risk of major smoking-related diseases. FDA briefing materials and staff presentations suggested regulators are leaning toward approving the proposed claim, with the agency stating that “the evidence suggests the proposed modified risk claim is scientifically accurate.”
“The FDA’s Center for Tobacco Product’s mission is to make smoking-related disease and death a part of America’s past,” said Keagan Lenihan, Chief External Affairs Officer for PMI U.S. “Smoke-free products, like Zyn, play a critical role in helping CTP achieve this mission and provide adults who smoke with important information to guide their choices and a real opportunity to change.”
The proposed language would allow PMI to say that using Zyn instead of cigarettes reduces the risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis. FDA scientists said the “totality of the evidence” shows Zyn contains substantially lower levels of harmful chemicals than cigarettes, and that consumer research suggests the claim increases awareness of reduced risks without misleading users into believing the product is risk-free. The agency also noted that youth nicotine pouch use remains relatively low, at 2.4% of U.S. high school students in 2024, and that exposure to the proposed claim did not increase young adults’ intentions to use Zyn. PMI executives argued that clearer communication of relative risk could help smokers move away from combustible products, drawing comparisons to Swedish snus, which received an MRTP designation in 2019 and has been linked to Sweden’s low smoking rates.
However, members of the independent TPSAC panel raised concerns about gaps in long-term data and whether reduced-risk marketing would meaningfully accelerate smoking cessation in the U.S. Public health advocates also warned about the potential appeal of flavored pouches, discreet use, and social-media promotion to underage users. While panelists generally agreed that Zyn is far less harmful than cigarettes, they questioned whether the evidence shows that marketing claims will drive widespread switching. The FDA is not bound by the panel’s non-binding recommendations and has not set a deadline for its final decision, which will determine whether PMI can formally promote Zyn as a reduced-risk product to adult smokers.
“While the relatively expedited timeline for this MRTP review is encouraging, the fact that the TPSAC did not vote on a recommendation makes me question the reason for these meetings moving forward,” said Laura Leigh Oyler, VP of Regulatory Affairs for Haypp Group, whose subsidiaries sell nicotine pouches online. “The science, and the many public speakers who supported the authorization were clear: Americans deserve honest messaging around these products and their impacts on harm reduction.”
-
Haypp Tabs De Prado as President of U.S. Market
Today (January 19), Haypp Group announced the appointment of Gabriel De Prado as president of its U.S. market, effective January 9. The parent company of Nicokick.com and Northerner.com, Haypp said the move is intended to accelerate growth in the nicotine pouch category.
De Prado, who previously served as Chief Commercial Officer, will oversee U.S. business operations with a mandate to strengthen commercial execution, deepen regulatory engagement, and further position Haypp as a leading compliant retailer in the fast-growing U.S. market. Chief Executive Officer Gavin O’Dowd said the appointment comes at a pivotal moment for the company’s U.S. expansion, citing De Prado’s international leadership experience, commercial discipline, and expertise in highly regulated sectors. De Prado brings more than 20 years of experience across Latin America and Europe, including senior roles at British American Tobacco, where he led strategic planning, consumer insights, and commercial execution across multiple markets.
During his tenure as Haypp Group’s CCO, De Prado led commercial operations across six countries, supported revenues exceeding €300 million, and built the company’s global insights and analytics function.
“Responsible growth isn’t optional in this category, it’s fundamental,” De Prado said. “My priorities are clear: disciplined growth, top-tier talent, and setting the highest standard for modern oral nicotine in e-commerce, while continuously listening to and adapting for the American consumer.”
-
Haypp Working to Increase Efficiency, Sustainability in Industry
Haypp released its latest Sustainability Report, outlining measured progress in product quality controls and supply chain transparency as the company expands in the tobacco-free nicotine category. The report notes that all new nicotine pouch products launched since 2024 have been tested against internal and relevant standards, reflecting efforts to improve consistency and information availability in a fast-growing segment.
“As the global leader in consumer insights within our field, we are uniquely positioned to influence and support the development of more sustainable products and services throughout the supply chain,” said Markus Lindblad, Haypp’s head of legal and external affairs. “Our ambition is to make sure that our growth can help positively influence the evolution of the nicotine pouch category towards a responsible and sustainable future.”
The company also reports advances in mapping transport-related emissions, with data now collected from most logistics and last-mile delivery partners, and ongoing supplier screening under its Business Partner Code of Conduct.
-
Haypp Says Mint and Berry Flavors Dominated UK Alternatives
UK online retailer Haypp released its “2025 Wrapped” sales data, revealing that mint flavors dominated nicotine pouch purchases while berry flavors led among vape users. Peppermint accounted for 24% of nicotine pouch sales, followed by spearmint at 14%, while cold mint (13%) and blueberry (12%) were the most popular vape flavors. The data highlights the role of flavor variety in encouraging smokers to switch to alternative nicotine products, according to the company.
Brand preferences in 2025 favored established names, with Velo (35%) and Nordic Spirit (14%) leading the nicotine pouch category, and Elf Bar (28%) and Vuse (25%) topping vape sales. Haypp said the findings underscore the importance of flavor diversity for adult consumers transitioning away from cigarettes, as policymakers consider future tobacco and vape regulations in the UK.
-
Youth-Focused Bans Hurt Older Vapers: Haypp Survey
“Much of the debate on the Tobacco and Vapes Bill is focused on restricting youth access to vapes,” Haypp Group said in a press release announcing its latest survey. “While there are legitimate concerns around underage access to vapes, the introduction of broad product restrictions or bans may inadvertently exclude older segments of the population and impact the number of older smokers switching to vapes.”
In surveying 501 adult vape users in the UK, Haypp data found 87% of vapers aged 55 and over started vaping to quit smoking, compared with much lower rates in younger groups. The over-55 cohort was also the most positive about switching, with 92% saying they felt better after moving from cigarettes, and 55% citing health as the main benefit.
The findings suggest older smokers—who face higher long-term health risks—could be disproportionately affected by product bans that limit access to regulated alternatives. Haypp said policymakers should consider more targeted youth protections while preserving access and accurate information for adult smokers seeking to switch.
-
Restricting Vapes Drives Smokers Back to Cigarettes: Opinion
A new commentary by Markus Lindblad, Head of External Affairs at Haypp Group, warns that parts of the UK’s Tobacco and Vapes Bill could backfire by driving some adults back to smoking. The bill, one of the world’s toughest anti-tobacco measures, includes a generational smoking ban for anyone born after 1 January 2009, new licensing rules, and tighter advertising limits. But Lindblad argues that proposed powers to restrict vape and nicotine-product flavors risk undermining the country’s smoke-free ambitions.
“Flavors aren’t just a marketing tool; they are a behavioral and psychological aid that help smokers make the transition away from cigarettes,” Lindblad said. “When a smoker switches to vaping, the experience of flavor, combined with the absence of smoke and tar, creates a sense of progress and separation from the old habit. Removing that variety reduces satisfaction, increases relapse risk, and ultimately undermines harm-reduction goals.”
Citing recent U.S. research, he says multiple large-scale studies show that state-level flavor bans reduce vaping but also lead to measurable increases in cigarette use. One JAMA study found that flavor restrictions were followed by higher smoking rates, while a 2024 analysis of 376,963 young adults reported a 3.6-point drop in daily vaping alongside a 2.2-point rise in daily smoking. Yale researchers similarly linked flavor bans to declining vape sales and rising cigarette sales across 44 states.
Haypp’s own UK survey found that nearly one-third of vapers cite taste as a key advantage of vaping, and 28% say flavor is their top purchasing factor. When asked how they would respond to a flavor ban, almost a quarter said they would return to smoking — a result Lindblad says should concern public-health officials. He concludes that rather than banning flavors, policymakers should strengthen age checks, tighten marketing rules, and improve labeling — measures aimed at youth access without limiting options for adults trying to quit smoking.